TEXT OF STORY
Doug Krizner: The controversial diabetes drug Avandia has been a problem for its maker, GlaxoSmithKline. Research has concluded the drug carries the risk of heart attack. Now, the British pharmaceutical giant may have to cut its sales force in response. From London, Stephen Beard reports.
Stephen Beard: Glaxo is still insisting that what was once its second-best selling drug is safe. But the company is nevertheless revising its marketing plans. One analyst quoted in the British press suggests that Glaxo could cut its Avandia sales force in the U.S. by 5 percent.
Sales of the drug have slumped, and its future looks uncertain. A study by a leading cardiologist at the Cleveland Clinic has raised serious concerns. He warned that patients on Avandia were much more likely to have a heart attack or stroke. Another study by German researchers came to the same conclusion.
The U.S. Food and Drug Administration is considering the matter. Some of the FDA’s advisors have already recommended that Avandia carry a health warning.
In London, this is Stephen Beard for Marketplace.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.